The risk of developing type 2 diabetes mellitus (DM) appears to be significantly less among olanzapine recipients than clozapine recipients

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1208, 2008-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A quick-release formulation of bromocriptine [Cycloset] appears to be a promising new treatment modality for type 2 diabetes mellitus (T2DM)

By  

Inpharma, Vol. 1, Iss. 1655, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

DM programme effective in type 2 diabetes mellitus

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 354, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Clozapine: Type 2 diabetes mellitus: 2 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1061, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Pioglitazone provides greater long-term glycaemic control than glibenclamide [glyburide] in patients with type 2 diabetes mellitus (T2DM)

By  

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

A fixed combination of rosiglitazone plus metformin improves glycaemic control and cardiovascular risk factors in patients with type 2 diabetes mellitus (T2DM)

By  

Inpharma, Vol. 1, Iss. 1546, 2006-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite